Chikujountanto for Cough of COVID-19 ; a Case Series
- VernacularTitle:COVID-19の咳嗽に対する竹筎温胆湯の使用経験
- Author:
Rie ONO
1
;
Shin TAKAYAMA
2
;
Ryutaro ARITA
3
;
Akiko KIKUCHI
1
;
Minoru OSAWA
2
;
Natsumi SAITO
4
;
Satoko SUZUKI
1
;
Tadashi ISHII
2
Author Information
- Keywords: chikujountanto; Kampo; cough; COVID-19
- From:Kampo Medicine 2023;74(1):67-74
- CountryJapan
- Language:Japanese
- Abstract: Prolonged cough in coronavirus disease 2019 (COVID-19) is not only uncomfortable for patients, but also prolongs the length of stay in an isolation facility. This results in delays in patients' return to their daily life. Therefore, the prompt treatment of cough is important. In this report, we used Japanese traditional (Kampo) medicine, chikujountanto for the treatment of cases with residual cough, airway secretions, slight fever, anxiety, and insomnia, several days after the onset of coronavirus. From October 2020 to September 2021, we prescribed chikujountanto for thirty-three COVID-19 patients with prolonged cough in an isolation facility. Seven patients (6 women and 1 man with ages ranging 37-70 years) were treated with no other medication. Comorbid symptoms included slight fever, sputum, sore throat, nasal discharge, headache, anxiety/insomnia, and taste/olfactory disorders. The start date of treatment ranged from 9 to 21 days after the onset of COVID-19, and the time until cough and comorbid symptoms improved to values less than NRS 2 or less, was 2 to 6 days after treatment. Three patients had persistent cough and needed to switch to other medication. In COVID-19, chikujountanto may be useful for coughing during the period when the peak of the viral proliferative phase has passed but airway inflammation is still present.
